Every investigational drug undergoes clinical developmental stages (e.g., Phase 1, Phase 2 and Phase 3), and the safety of the study subjects is a key concern in each clinical trial. Safety profiles ...
BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Hosted on MSN
Tiziana reports clean FDA safety update for intranasal foralumab after 37.4 patient-years of exposure
Tiziana Life Sciences ( (TLSA)) just unveiled an update. On December 29, 2025, Tiziana Life Sciences reported that it has filed its seventh annual Development Safety Update Report with the U.S. Food ...
Pharmaceutical industry stakeholders urged the US Food and Drug Administration (FDA) to better align its investigational new drug application (IND) annual reporting proposal with the International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results